Eledon Net Debt vs Intangible Assets Analysis

ELDN Stock

USD 3.44 0.31 9.90%

Eledon Pharmaceuticals financial indicator trend analysis is much more than just examining Eledon Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eledon Pharmaceuticals is a good investment. Please check the relationship between Eledon Pharmaceuticals Net Debt and its Intangible Assets accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.

Net Debt vs Intangible Assets

Net Debt vs Intangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eledon Pharmaceuticals Net Debt account and Intangible Assets. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Eledon Pharmaceuticals' Net Debt and Intangible Assets is -0.15. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Intangible Assets in the same time period over historical financial statements of Eledon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eledon Pharmaceuticals' Net Debt and Intangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Eledon Pharmaceuticals are associated (or correlated) with its Intangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Intangible Assets has no effect on the direction of Net Debt i.e., Eledon Pharmaceuticals' Net Debt and Intangible Assets go up and down completely randomly.

Correlation Coefficient

-0.15

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Most indicators from Eledon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eledon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.At this time, Eledon Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 7th of August 2025, Issuance Of Capital Stock is likely to grow to about 140 M, while Selling General Administrative is likely to drop about 11.2 M.

Eledon Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock Total Equity	Common Stock	Short Term Investments	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue	Other Assets
Total Assets		0.4	0.51	0.93	0.58	-0.65	-0.54	0.51	0.65	0.85	0.0	0.83	0.53	-0.16	0.67	0.8	-0.09	0.58	0.83	-0.2	0.32	0.22	-0.43	0.83	0.41	0.5
Other Current Liab	0.4		0.9	0.32	0.73	-0.02	-0.73	0.77	0.01	0.08	-0.15	0.71	0.72	0.17	0.61	0.76	0.27	0.73	0.71	-0.07	0.72	0.75	-0.07	0.4	0.67	-0.24
Total Current Liabilities	0.51	0.9		0.43	0.87	-0.01	-0.9	0.95	0.01	0.23	-0.09	0.81	0.9	0.16	0.55	0.87	0.27	0.87	0.81	-0.17	0.86	0.79	-0.21	0.6	0.84	-0.14
Total Stockholder Equity	0.93	0.32	0.43		0.55	-0.71	-0.44	0.41	0.71	0.8	0.2	0.76	0.39	-0.49	0.66	0.74	-0.43	0.55	0.77	-0.32	0.14	0.01	-0.53	0.77	0.26	0.52
Property Plant And Equipment Net	0.58	0.73	0.87	0.55		-0.06	-0.83	0.84	0.06	0.47	0.01	0.69	0.84	-0.02	0.67	0.87	0.09	1.0	0.7	-0.31	0.62	0.51	-0.43	0.73	0.66	-0.12
Net Debt	-0.65	-0.02	-0.01	-0.71	-0.06		-0.09	0.0	-1.0	-0.5	0.01	-0.52	0.12	0.39	-0.16	-0.27	0.37	-0.06	-0.52	-0.06	0.19	0.26	0.1	-0.35	0.15	-0.59
Retained Earnings	-0.54	-0.73	-0.9	-0.44	-0.83	-0.09		-0.85	0.09	-0.37	0.14	-0.71	-0.92	-0.17	-0.61	-0.86	-0.28	-0.83	-0.72	0.17	-0.82	-0.71	0.28	-0.68	-0.78	0.12
Accounts Payable	0.51	0.77	0.95	0.41	0.84	0.0	-0.85		-0.01	0.3	0.02	0.79	0.94	0.22	0.43	0.85	0.33	0.84	0.8	-0.3	0.88	0.79	-0.33	0.69	0.9	-0.02
Cash	0.65	0.01	0.01	0.71	0.06	-1.0	0.09	-0.01		0.5	-0.02	0.52	-0.12	-0.4	0.16	0.27	-0.38	0.06	0.51	0.06	-0.19	-0.27	-0.1	0.34	-0.15	0.59
Non Current Assets Total	0.85	0.08	0.23	0.8	0.47	-0.5	-0.37	0.3	0.5		0.07	0.53	0.41	-0.14	0.61	0.64	-0.1	0.47	0.53	-0.32	0.06	-0.03	-0.6	0.86	0.12	0.53
Non Currrent Assets Other	0.0	-0.15	-0.09	0.2	0.01	0.01	0.14	0.02	-0.02	0.07		-0.03	0.03	-0.47	0.09	0.04	-0.48	0.01	-0.03	-0.89	-0.25	-0.29	-0.75	0.17	0.07	0.12
Cash And Short Term Investments	0.83	0.71	0.81	0.76	0.69	-0.52	-0.71	0.79	0.52	0.53	-0.03		0.73	-0.01	0.54	0.89	0.09	0.69	1.0	-0.15	0.68	0.59	-0.28	0.73	0.67	0.32
Common Stock Shares Outstanding	0.53	0.72	0.9	0.39	0.84	0.12	-0.92	0.94	-0.12	0.41	0.03	0.73		0.3	0.57	0.88	0.4	0.84	0.73	-0.36	0.86	0.79	-0.42	0.73	0.86	-0.12
Non Current Liabilities Total	-0.16	0.17	0.16	-0.49	-0.02	0.39	-0.17	0.22	-0.4	-0.14	-0.47	-0.01	0.3		-0.21	-0.01	0.99	-0.02	-0.01	0.31	0.49	0.61	0.35	-0.04	0.33	-0.2
Other Current Assets	0.67	0.61	0.55	0.66	0.67	-0.16	-0.61	0.43	0.16	0.61	0.09	0.54	0.57	-0.21		0.77	-0.14	0.67	0.55	-0.34	0.24	0.25	-0.48	0.63	0.31	-0.08
Other Stockholder Equity	0.8	0.76	0.87	0.74	0.87	-0.27	-0.86	0.85	0.27	0.64	0.04	0.89	0.88	-0.01	0.77		0.09	0.87	0.9	-0.36	0.67	0.59	-0.52	0.87	0.69	0.17
Total Liab	-0.09	0.27	0.27	-0.43	0.09	0.37	-0.28	0.33	-0.38	-0.1	-0.48	0.09	0.4	0.99	-0.14	0.09		0.09	0.09	0.29	0.58	0.69	0.32	0.03	0.42	-0.21
Property Plant And Equipment Gross	0.58	0.73	0.87	0.55	1.0	-0.06	-0.83	0.84	0.06	0.47	0.01	0.69	0.84	-0.02	0.67	0.87	0.09		0.7	-0.31	0.62	0.51	-0.43	0.73	0.66	-0.12
Total Current Assets	0.83	0.71	0.81	0.77	0.7	-0.52	-0.72	0.8	0.51	0.53	-0.03	1.0	0.73	-0.01	0.55	0.9	0.09	0.7		-0.16	0.68	0.59	-0.29	0.73	0.67	0.31
Common Stock Total Equity	-0.2	-0.07	-0.17	-0.32	-0.31	-0.06	0.17	-0.3	0.06	-0.32	-0.89	-0.15	-0.36	0.31	-0.34	-0.36	0.29	-0.31	-0.16		0.03	0.08	0.92	-0.51	-0.26	-0.13
Common Stock	0.32	0.72	0.86	0.14	0.62	0.19	-0.82	0.88	-0.19	0.06	-0.25	0.68	0.86	0.49	0.24	0.67	0.58	0.62	0.68	0.03		0.96	0.03	0.41	0.89	-0.15
Short Term Investments	0.22	0.75	0.79	0.01	0.51	0.26	-0.71	0.79	-0.27	-0.03	-0.29	0.59	0.79	0.61	0.25	0.59	0.69	0.51	0.59	0.08	0.96		0.11	0.29	0.82	-0.23
Short Long Term Debt Total	-0.43	-0.07	-0.21	-0.53	-0.43	0.1	0.28	-0.33	-0.1	-0.6	-0.75	-0.28	-0.42	0.35	-0.48	-0.52	0.32	-0.43	-0.29	0.92	0.03	0.11		-0.72	-0.23	-0.33
Net Tangible Assets	0.83	0.4	0.6	0.77	0.73	-0.35	-0.68	0.69	0.34	0.86	0.17	0.73	0.73	-0.04	0.63	0.87	0.03	0.73	0.73	-0.51	0.41	0.29	-0.72		0.5	0.44
Current Deferred Revenue	0.41	0.67	0.84	0.26	0.66	0.15	-0.78	0.9	-0.15	0.12	0.07	0.67	0.86	0.33	0.31	0.69	0.42	0.66	0.67	-0.26	0.89	0.82	-0.23	0.5		-0.09
Other Assets	0.5	-0.24	-0.14	0.52	-0.12	-0.59	0.12	-0.02	0.59	0.53	0.12	0.32	-0.12	-0.2	-0.08	0.17	-0.21	-0.12	0.31	-0.13	-0.15	-0.23	-0.33	0.44	-0.09

Click cells to compare fundamentals

Eledon Pharmaceuticals Account Relationship Matchups

Eledon Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	197.2M	170.5M	92.8M	125.9M	177.4M	89.9M
Other Current Liab	829K	1.9M	3.5M	2.5M	5.4M	5.7M
Total Current Liabilities	2.5M	4.4M	6.5M	3.9M	11.6M	12.2M
Total Stockholder Equity	190.6M	164.0M	84.2M	83.4M	118.1M	66.1M
Property Plant And Equipment Net	138K	768K	739K	365K	926K	972.3K
Net Debt	(114.1M)	(84.1M)	(55.7M)	(4.2M)	(19.6M)	(20.6M)
Retained Earnings	(80.4M)	(114.9M)	(202.9M)	(243.2M)	(355.6M)	(337.8M)
Accounts Payable	1.4M	1.8M	2.2M	967K	5.8M	6.1M
Cash	114.2M	84.8M	56.4M	4.6M	20.5M	19.5M
Non Current Assets Total	81.6M	82.2M	33.3M	69.8M	33.7M	26.0M
Non Currrent Assets Other	383K	400K	150K	186K	363K	316.7K
Cash And Short Term Investments	114.2M	84.8M	56.4M	51.1M	140.2M	147.2M
Common Stock Shares Outstanding	1.5M	14.8M	14.3M	24.6M	48.5M	51.0M
Liabilities And Stockholders Equity	197.2M	170.5M	92.8M	125.9M	177.4M	89.9M
Non Current Liabilities Total	4.1M	2.2M	2.1M	38.6M	47.7M	50.1M
Other Current Assets	1.3M	3.5M	3.1M	5.0M	3.6M	2.3M
Other Stockholder Equity	271.0M	278.9M	287.0M	326.6M	473.6M	497.3M
Total Liab	6.6M	6.6M	8.6M	42.5M	59.3M	62.2M
Property Plant And Equipment Gross	138K	768K	739K	365K	926K	972.3K
Total Current Assets	115.6M	88.3M	59.5M	56.1M	143.7M	150.9M
Common Stock	13K	15K	14K	24K	60K	63K
Short Long Term Debt Total	144K	769K	746K	383K	954K	773.4K
Net Tangible Assets	12.6M	9.5M	109.6M	83.0M	95.4M	100.2M
Short Term Debt	288K	738K	726K	383K	314K	298.3K
Property Plant Equipment	14K	321K	138K	768K	883.2K	927.4K
Net Invested Capital	190.6M	164.0M	84.2M	83.4M	118.1M	94.0M
Net Working Capital	113.1M	83.9M	53.0M	52.2M	132.2M	138.8M
Capital Stock	13K	15K	14K	24K	60K	63K
Capital Lease Obligations	144K	769K	746K	383K	954K	608.7K

When determining whether Eledon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eledon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eledon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eledon Pharmaceuticals Stock:

How To Invest In Eledon

Details

Is Eledon Stock a good investment?

Details

What is Eledon Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.04)

Return On Assets

(0.40)

Return On Equity

(0.38)

The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Eledon Net Debt vs Intangible Assets Analysis

Net Debt vs Intangible Assets

Net Debt vs Intangible Assets Correlation Analysis

Correlation Coefficient

Net Debt

Intangible Assets

Eledon Pharmaceuticals fundamental ratios Correlations

Eledon Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eledon Pharmaceuticals fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Short Term Investments	+ 0.96	Common Stock
Accounts Payable	+ 0.95	Total Current Liabilities
Common Stock Shares Outstanding	+ 0.94	Accounts Payable

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Retained Earnings	- 0.9	Total Current Liabilities
Common Stock Total Equity	- 0.89	Non Currrent Assets Other
Other Stockholder Equity	- 0.86	Retained Earnings
Accounts Payable	- 0.85	Retained Earnings